China Diabetes Care Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The China Diabetes Care Drugs Market is segmented into drugs (insulin (Basal or Long Acting insulins, Bolus or Fast Acting insulins, traditional human insulins, and biosimilar insulins), oral anti-diabetic drugs (Biguanides, Alpha-Glucosidase inhibitors, Dopamine D2 receptor agonist, SGLT-2 inhibitors, DPP-4 inhibitors, Sulfonylureas, and Meglitinides), non-insulin injectable drugs (GLP-1 receptor agonists and Amylin Analogue), and combination drugs (insulin combinations and oral combinations)). The market provides the value (in USD million) for the above-mentioned segments.

China Diabetes Care Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

China Diabetes Care Drugs Industry Overview

The China Diabetes Care Drugs Market is moderately fragmented, with major manufacturers, namely Eli Lilly, Sanofi, Novo Nordisk, AstraZeneca, and other generic players, holding a presence in the region. The market for oral drugs, like Sulfonylureas and Meglitinides, comprises more generic players. The intensity of competition among the players is high, as each player is striving to develop new drugs and offer them at competitive pricing. Furthermore, players are tapping into new markets to increase their market shares, especially in emerging economies where the demand is very high compared to the supply.

China Diabetes Care Drugs Market Leaders

  1. Eli Lilly

  2. Boehringer Ingelheim

  3. Astrazeneca

  4. Sanofi

  5. Novo Nordisk

  6. *Disclaimer: Major Players sorted in no particular order
China Diabetes Care Drugs Market Concentration

China Diabetes Care Drugs Market Report Snapshots

80% of our clients seek made-to-order reports. How do you want us to tailor yours?